Somatic Genetic Testing Market Report 2025

The somatic genetic testing market size has grown rapidly in recent years. It will grow from $6.81 billion in 2024 to $7.78 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth during the historic period can be attributed to increasing awareness of genetic disorders, the rising prevalence of cancer, greater adoption of genetic testing in clinical settings, the expansion of healthcare infrastructure, and growing patient demand for personalized treatment.

The somatic genetic testing market size is expected to see rapid growth in the next few years. It will grow to $13.13 billion in 2029 at a compound annual growth rate (CAGR) of 14%. The growth in the forecast period can be attributed to the increasing focus on early disease detection, rising collaborations between biotechnology and pharmaceutical companies, the expansion of public-private partnerships, and greater availability of advanced diagnostic tools. Key trends expected during this period include technological progress in sequencing, innovations in bioinformatics and artificial intelligence, increased investment in research and development, the advancement of non-invasive testing methods, and continued innovations in next-generation sequencing platforms.

The rising incidence of cancer is expected to drive the growth of the somatic genetic testing market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing burden of cancer is linked to lifestyle factors such as unhealthy diets, smoking, physical inactivity, and excessive alcohol consumption. Somatic genetic testing supports cancer diagnosis by identifying tumor-specific genetic mutations, enabling targeted and personalized treatment strategies. It also reduces the need for invasive procedures through advanced technologies, enhancing diagnostic accuracy and improving patient outcomes. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency, reported that the number of cancer cases diagnosed in Australia reached 160,570 in 2022, an increase of 3,789 cases from 156,781 in 2021. Consequently, the growing incidence of cancer is fueling demand for somatic genetic testing.

Companies in the somatic genetic testing market are focusing on advanced diagnostic solutions such as liquid biopsy tests to improve precision, enable early detection, and reduce reliance on invasive procedures. Liquid biopsy refers to a non-invasive method of analyzing circulating tumor DNA (ctDNA) or other biomarkers in blood samples to identify cancer-related genetic mutations. For instance, in September 2024, Strand Life Sciences, an India-based genomics and bioinformatics company, introduced the Somatic Advantage 74 Liquid Biopsy (SA74 LB) test, a next-generation sequencing (NGS)-based solution designed to detect ctDNA from blood samples. This test identifies somatic mutations across 74 key cancer-related genes, supporting personalized cancer care by pinpointing actionable mutations, monitoring treatment response, and detecting minimal residual disease (MRD) without traditional tissue biopsies. It facilitates precision oncology by guiding targeted therapies and tracking disease progression or resistance in real time.

In December 2022, Prenetics Global Limited, a China-based genetic testing company, acquired ACT Genomics Holdings Company Limited for an undisclosed sum. Through this acquisition, Prenetics gains access to ACT Genomics’ cancer testing technologies, including NGS, bioinformatics, and genome profiling, to enhance both somatic and germline testing across Asia and beyond. ACT Genomics Holdings Company Limited, based in Taiwan, specializes in somatic genetic testing for cancer patients.

Major players in the somatic genetic testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., QIAGEN N.V., Exact Sciences Corp., ARUP Laboratories Inc., Natera Inc., Myriad Genetics Inc., Fulgent Genetics Inc., Invitae Corporation, NeoGenomics Laboratories Inc., Guardant Health Inc., MedGenome Labs Ltd., Caris Life Sciences Inc., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Invivoscribe Inc., Centogene N.V., and Circulogene Theranostics LLC.

North America was the largest region in the somatic genetic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in somatic genetic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the somatic genetic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

Somatic genetic testing refers to the comprehensive analysis of genetic mutations that occur in non-reproductive (somatic) cells over a person’s lifetime, most often within tumor tissues. It plays a vital role in cancer diagnosis and treatment by detecting specific genetic alterations that can be targeted with personalized therapies, while also helping to predict disease progression and support clinical decision-making.

The key types of somatic genetic testing include targeted gene panels, whole exome sequencing, whole genome sequencing, carrier screening, and others. Targeted gene panels involve analyzing a defined group of genes linked to a particular disease or condition, allowing for accurate and cost-effective diagnosis. This testing can be performed using a range of sample types, such as tissue-based samples, blood samples, bone marrow aspirates, and others. It employs advanced technologies including polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and more. Somatic genetic testing is applied in various areas such as cancer diagnosis, cardiovascular diseases, neurological disorders, inherited genetic conditions, and others, and is utilized by end users including hospitals, clinical laboratories, research institutes, at-home testing providers, and others.

The somatic genetic testing market research report is one of a series of new reports that provides somatic genetic testing market statistics, including somatic genetic testing industry global market size, regional shares, competitors with a somatic genetic testing market share, detailed somatic genetic testing market segments, market trends and opportunities, and any further data you may need to thrive in the somatic genetic testing industry. This somatic genetic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The somatic genetic testing market consists of revenues earned by entities by providing services such as tumor profiling, biomarker identification, companion diagnostic testing, mutation analysis, and next-generation sequencing (NGS) for personalized cancer therapy selection and treatment monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The somatic genetic testing market also includes sales of testing kits, reagents, assay panels, sequencing instruments, software tools for data analysis, and laboratory consumables used in the detection and interpretation of somatic mutations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.